showed that down expression of PBRM1 could promote tumorigenesis in nude mice. Pathway gene chip analysis revealed that PBRM1 knockdown resulted in the chemokine/chemokine receptor interaction pathway with the most different gene expression. Increased protein levels of IL6ST and CCL2, whereas the protein levels of IL8, IL6 and CXCL2 were decreased.
INTRODUCTION AND OBJECTIVES: HOXA11 is a member of HOX transcription factors, the HOX genes encode transcription factors that play an essential role in regulating cell differentiation and proliferation. The hypermethylation of HOXA11 promoter region has been reported in various cancers. However, the epigenetic alteration and function of HOXA11 in human renal cell carcinoma (RCC) has not been explained. Therefore, to investigate the expression and function of HOXA11 is significant.
METHODS: PCR and IHC were used to check the expression of HOXA11 in RCC cells and tissues. To detect the methylation status of HOXA11 promoter, MSP (methylation specific PCR) and BGS (bisulfite genomic sequencing) were used. We also used colony formation, CCK8, wound healing, Transwell, Annexin V apoptosis assay and Western-blot to assess the function and related mechanism of HOXA11 in renal cell carcinoma. Finally, we used Fisher's exact test, Student's t test and Chi-square test to analyze the correlation between clinical features and HOXA11 promoter methylation.
RESULTS: HOXA11 was down-regulated by promoter aberrant methylation in both RCC cell lines and tissues compared with normal kidney cell line and tissues. HOXA11 methylation was found at higher prevalence (70.5%, 68/95) in human RCC tissues than in adjacent nonmalignant renal tissues (13%, 3/23) and associated with higher TNM classification of RCC (p<0.05). In addition, restoration of HOXA11 expression reduced the proliferation, colony formation, migration and invasion abilities and induced RCC cells apoptosis. Moreover, HOXA11 was found to inhibit Wnt signaling.
CONCLUSIONS: Our study demonstrated that HOXA11 function as a tumor suppressor in RCC which is mainly regulated by epigenetics. The objective of our study was to discover novel insights into the molecular mechanism of tumor suppression by FLCN.
Source of
METHODS: To gain further insight into the cellular function of FLCN, we isolated FLCN-containing protein complexes from the lysates of the FLCN-/-UOK257 human clear cell renal cell carcinoma cell line and its FLCN-replete isogenic derivative cells. Mass spectrometric analysis of affinity-purified complexes indicated that FLCN associates with several factors of the protein translation machinery, including the protein translation initiation factors.
RESULTS: Here we report that FLCN localizes to the polysomes and associates with factors regulating the initiation of protein translation, including EIF2G and EIF5B. The FLCN C-terminal domain, which is deleted by tumor-associated FLCN mutations, is necessary for the interaction of FLCN with EIF2G and EIF5B. Reintroduction of wild type but not a C-terminus FLCN mutant into FLCN-/-cells results in suppression of serum or amino acid stimulated protein translation, independently of mTORC1/2 activity. CONCLUSIONS: Our data provide insights into a novel mechanism of cell growth restriction by FLCN. Here we report that FLCN binds to protein translation initiation factors, resulting in repression of protein translation, downstream of mTORC1. This observation predicts that mTOR inhibitors may have limited efficacy in treating FLCN-related RCC and highlights protein translation as a therapeutic target for FLCNrelated tumors.
Source of Funding: This work was supported by the Mildred Scheel Fellowship from the German Cancer Aid (MS) and NIH/NCI 1R01CA104574 (OI).
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